2023-12-12 07:30:06 ET
DENVER, Colo., Dec 12, 2023 ( www.247marketnews.com )- IN8bio, Inc. IN8bio Inc (NASDAQ: INAB) reported, after yesterday’s market close, positive updated data from its Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies, which was presented in a poster presentation at the 65th ASH Annual Meeting & Exposition.
IN8bio is trading at $1.54, up $0.26 (+20.31%), on 696K shares traded.
Its 52-week range is $0.65 to $3.9499. It’s trading at a multi month high and can now begin to challenge its July and June trading levels, but the volume needs to pick up to have a chance and probably best to scalp.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported …
The post Positive Phase 1 Trial Clinical Update Could Fuel Run appeared first on 24/7 Market News .
For further details see:
Positive Phase 1 Trial Clinical Update Could Fuel Run